




Homo-PROTACs for the Chemical Knockdown of Cereblon

Stefanie Lindner

60th ASH Annual Meeting and Exposition
December 1, 2018
San Diego , CA

IMiDs modulate substrate specificity of the CRBN E3 ligase

Thalidomide
lenalidomide
omalizomide



Ito *et al.*, **2010**, *Science*
Krönke *et al.*, **2014**, *Science*
Lu *et al.*, **2014**, *Science*
Krönke *et al.*, **2015**, *Nature*
Donovan *et al.*, **2018**, *Elife*
Matyskiela *et al.*, **2018**, *Nat Chem Biol.*

Proteolysis Targeting Chimeras (PROTACs)

Bifunctional molecules for degradation of proteins of interest (POI)

POI
ligand

Thalidomide
Lenalidomide
Pomalidomide


linker



Sakamoto *et. al.*, **2001**, *PNAS*
Schneekloth *et. al.*, **2004**, *J Am Chem Soc.*
Lu *et al.*, **2015**, *Chem Biol*
Winter *et al.*, **2017**, *Mol Cell.*

Proteolysis Targeting Chimeras (PROTACs)


Bifunctional molecules for degradation of proteins of interest (POI)



Sakamoto *et. al.*, **2001**, *PNAS*
Schneekloth *et. al.*, **2004**, *J Am Chem Soc.*
Lu *et al.*, **2015**, *Chem Biol*
Winter *et al.*, **2017**, *Mol Cell.*

Homodimeric pomalidomide-based PROTACs


Linker (size X)



Homo-bifunctional molecules

Pomalidomide

Pomalidomide





Homodimeric pomalidomide-based PROTACs

corresponding linker substructures





Linker	No. of linear linker atoms	CRBN degradation	IKZF1 degradation
	8	++	+
	10	+	++
	12	+	++
	13	+	++
	5	++	+

multiple myeloma cell line MM1S



LEN: Lenalidomide
POM: Pomalidomide


Pomalidomide-based Homo-PROTACs induce degradation of CRBN




Impact of Homo-PROTAC 15a on the cellular proteome

- based quantitative proteomics in MM1S cell line
concentration: 100nM
incubation: 3h







Homo-PROTAC 15 vs. DMSO (3h)





Pomalidomide vs. DMSO (3h)



CRBN knockdown has no effect on cell proliferation



Compound 15a antagonizes the effects of IMiDs on multiple myeloma cells




Conclusions

IMiD-based Homo-PROTACs induce specific CRBN ubiquitination and degradation

Chemical CRBN degradation had no effect on cancer cell proliferation

Homo-PROTAC abrogates IMiD effects in multiple myeloma



Homodimeric pomalidomide-based compounds may help to:

- Identify CRBN's endogenous substrates and physiologic function
- Investigate the molecular mechanism of IMiDs
- Potential clinical application in obesity (Lee *et al.*, 2013, *Diabetes*)

Acknowledgment



Krönke Lab

Jan Krönke
Hannes Kehm
Simon Köpff
Tatjana Meyer
Linda Röhner
Yuen Lam Dora Ng
Imke Bauhuf
Stephan Bohl

Gütschow lab

Michael Gütschow
Christian Steinebach

Broad Institute of MIT and Harvard

Steven A. Carr
Namrata D. Udeshi
Deepak Mani

